适体
免疫原性
计算生物学
结合
药品
癌症治疗
化学
核糖核酸
药理学
癌症研究
纳米技术
分子生物学
癌症
抗体
生物
生物化学
免疫学
遗传学
材料科学
数学
数学分析
基因
作者
Jiaxuan He,Qiao Duan,Chunyan Ran,Ting Fu,Yuan Liu,Weihong Tan
标识
DOI:10.1016/j.apsb.2023.01.017
摘要
Aptamers are single-stranded DNA or RNA sequences that can specifically bind with the target protein or molecule via specific secondary structures. Compared to antibody-drug conjugates (ADC), aptamer‒drug conjugate (ApDC) is also an efficient, targeted drug for cancer therapy with a smaller size, higher chemical stability, lower immunogenicity, faster tissue penetration, and facile engineering. Despite all these advantages, several key factors have delayed the clinical translation of ApDC, such as in vivo off-target effects and potential safety issues. In this review, we highlight the most recent progress in the development of ApDC and discuss solutions to the problems noted above.
科研通智能强力驱动
Strongly Powered by AbleSci AI